Meta-Analysis
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7841-7850
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7841
Table 1 Design and patient characteristics of included clinical trials
PublicationStudy designSample (n)Age (yr)Male genderAdenocarcinomaDistal esophagusTumour length (cm)
Verschuur et al[16], 2006Prospective4265 ± 1460%76%21%7.8 ± 2.4
cohort
Kim et al[13], 2009Prospective1768 ± 894%33%39%6.1 ± 2.6
randomized
Park et al[15], 2010Prospective3267 ± 975%N/A53%N/A
cohort
Battersby et al[12], 2012Prospective557267%56%93%11.7 ± 2.5
cohort(stent length)
Kim et al[14], 2012Prospective4868 ± 1181%33%37%N/A
cohort
Mezes et al[11], 2014Retrospective56N/A61%38%55%N/A
cohort
Table 2 Event counts of tumour overgrowth, stent migration and complications encountered
PublicationTumour overgrowthStent migrationFood impactionReflux esophagitisAspiration pneumoniaEsophageal fistulaPerforationHemorrhage
Verschuur et al[16], 2006n = 2n = 3-n = 2n = 2-n = 1n = 1
Kim et al[13], 2009--n = 1--n = 1--
Park et al[15], 2010n = 5n = 1-n = 4n = 1n = 1--
Battersby et al[12], 2012n = 1n = 36%8%3%0.8%0.4%-
Kim et al[14], 2012n = 13n = 1n = 2n = 13n = 5n = 2--
Mezes et al[11], 2014n = 19n = 4---n = 1--
Table 3 Summary of the meta-analysis for all outcome measures with the random and fixed effects models
ParametersPooled estimates Random (95%CI)Pooled estimates Fixed (95%CI)I² heterogeneity
Technical success (%)97.2 (94.8-98.9)97.2 (94.9-98.9)Low (5.8%)
Overall complications (%)27.6 (20.7-35.2)28.1 (22.8-33.8)Moderate (41.9%)
Dysphagia score improvement (0-4)-2.00 [-2.29-(-1.72)]-1.94 [-2.04-(-1.84)]High (87.0%)
Migration (%)4.7 (2.5–7.7)4.7 (2.5–7.7)Low (0.0%)
Overgrowth (%)11.2 (3.7–22.1)12.3 (8.5–16.6)High (82.2%)